Case report: Massive hepatocellular carcinoma with complete response to the non-surgical systematic treatment strategy

Author:

Li Yun,Lai Yanzhen,Luo Xuqiang,Wu Jian,Wu Kunpeng,Ma Haiqing

Abstract

BackgroundThe five-year recurrence rate of hepatocellular carcinoma (HCC) remains as high as 70%. A complete clinical response has not been observed without surgical resection. Here, we report a rare case of clinical complete response and long-term survival in a patient with massive HCC receiving treatment with immunotherapy, anti-angiogenic therapy, and radiotherapy.Case descriptionA 38-year-old woman presented to our hospital for abdominal pain that persisted for 3 months. She was diagnosed as Barcelona Clinic Liver Cancer(BCLC) stage A, with a Cancer of the Liver Italian Program (CLIP) score of 3, American Joint Committee on Cancer (AJCC) Tumor-Node-Metastasis (TNM) staging systems stage IB. She refused surgical resection and trans-arterial chemoembolization and accepted a non-invasive systematic treatment strategy involving immunotherapy, anti-angiogenic therapy, and radiotherapy. Her tumor burden decreased, and she experienced partial response before radiotherapy. Following radiotherapy, she experienced a complete clinical response and has been alive for more than 36 months after her initial presentation. She is currently alive.ConclusionA non-invasive systematic treatment strategy is a potential radical treatment option for patients with massive HCC.

Publisher

Frontiers Media SA

Reference24 articles.

1. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017;Zhou;Lancet,2019

2. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020;Cao;Chin Med J (Engl),2021

3. Establishment and validation of a nomogram prediction model for early preoperative diagnosis of hepatocellular carcinoma with microvascular invasion;Yubo;Chin J Hepatobiliary Surg,2021

4. Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma;Pinato;Hepatology,2020

5. Neoadjuvant immunotherapy for hepatocellular carcinoma;Marron;J Hepatocell Carcinoma,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3